Chardan Capital Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $112.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its target price raised by stock analysts at Chardan Capital from $110.00 to $112.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Chardan Capital’s price target would indicate a potential upside of 33.35% from […]
More Stories
How to Recover a Disabled Instagram Account? Tips and Process
Losing access to your personal or business Instagram account can disrupt personal connections, professional outreach, or years of memories. Instagram...
How Payment Processing Fees Affect Ecommerce Profit Margins
Card fees take a larger share of an online store’s profit than its revenue line suggests. Publicly traded general retailers...
Ukraine, Russia and Europe: Why the Future of European Security Is at a Turning Point
European diplomacy faces important questions about security, peace and international cooperation. The war in Ukraine continues to shape Europe's political...
COP31: Can World Leaders Turn Climate Promises into Real Action?
Renewable energy investment is central to the international effort to reduce greenhouse gas emissions. Climate change has become one of...
Who Controls the Machines? The Global Debate Over AI-Powered Autonomous Weapons
Global Affairs and Technology | 16 November 2026 Artificial intelligence is creating new questions about human control, responsibility and the...
How Artificial Intelligence Is Reshaping Global Trade and Creating New Winners
Artificial intelligence is transforming semiconductor manufacturing, international investment and global trade. Image: Unsplash International Business and Technology Artificial intelligence is becoming...
